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Objectives: The Sarar cohort consists of patients with rheumatoid arthritis and juvenile idio-
pathic arthritis who underwent hip or knee arthroplasties at hospital SARAH-Brasília. The
objective of this study was to evaluate clinical and laboratory factors associated with dis-
ease  activity, functional capacity and radiological damage in rheumatoid arthritis patients,
participants in this cohort.
Methods: Cross-sectional study, with data collection achieved from medical records review.
Results: Thirty-two patients were included, with a mean time of disease onset of 240 months.
Nineteen patients underwent total knee and 17 total hip arthroplasty. There was a pos-
itive  correlation between maximum dose of methotrexate and Clinical Disease Activity
Index (R = −0.46, p = 0.011), and a negative one with Simpliﬁed Erosion and Narrowing Score
(R  = −0.58, p = 0.004). Simpliﬁed Erosion and Narrowing Score values were higher in patients
with rheumatoid factor (p = 0.005) and anti-cyclic citrullinated peptide antibody 3 positivity
(p  = 0.044), in those with higher rheumatoid factor (p = 0.037) and anti-cyclic citrullinated
peptide antibody 3 (p = 0.025) titers, and lower in patients with family history of rheumatoid
factor (p = 0.009). Health Assessment Questionnaire values were higher in older patients
(p  = 0.031). In multiple linear regression, only “maximum dose of methotrexate” and “fam-
ily  history” remained with signiﬁcant association with Simpliﬁed Erosion and Narrowing
Score (r2 = 0.73, p < 0.001 for both variables). In the model evaluating “Clinical Disease Activity
Index” only “maximum dose of methotrexate” remained signiﬁcantly associated (r2 = 0.35,
p  = 0.016).
Conclusion: In the Sarar cohort, clinical and laboratory factors were related to disease activity,
functional capacity and radiological damage, similar to studies evaluating patients withlower disease duration.
© 2015 Elsevier Editora Ltda. All rights reserved.
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Coorte  Sarar:  atividade  de  doenc¸a, capacidade  funcional  e  dano
radiológico  em  pacientes  com  artrite  reumatoide  submetidos  à
artroplastia  total  de  quadril  e  joelho
Palavras-chave:
Artrite reumatoide
Artroplastia
Dano radiológico
Capacidade funcional
r  e  s  u  m  o
Objetivos: A coorte Sarar é composta por pacientes portadores de artrite reumatoide (AR)
e  artrite idiopática juvenil (AIJ) submetidos a artroplastias de quadril e joelho no hospital
SARAH-Brasília. O objetivo deste estudo foi avaliar fatores clínicos e laboratoriais associa-
dos  à atividade de doenc¸a, capacidade funcional e dano radiológico em pacientes com AR,
participantes dessa coorte.
Métodos: Estudo transversal, com coleta de dados em revisão de prontuário.
Resultados: 32 pacientes foram incluídos, com tempo médio de início da doenc¸a de 240
meses. Dezenove pacientes foram submetidos a ATJ e 17, a ATQ. Foi encontrada correlac¸ão
positiva entre dose máxima de metotrexato (MTX) durante a evoluc¸ão e Clinical Disease
Activity Index (CDAI) (R = -0,46, p = 0,011) e negativa com Simpliﬁed Erosion and Narrowing
Score (SENS) (R = -0,58, p = 0,004). Valores de SENS foram maiores nos pacientes com fator
reumatoide (FR) (p = 0,005) e anticorpo anti-peptídeo cíclico citrulinado 3 (anti-CCP3) posi-
tivo  (p = 0,044), nos com maiores títulos de FR (p = 0,037) e Anti-CCP3 (p = 0,025) e menores
nos pacientes com história de familiar de AR (p = 0,009). Valores de HAQ foram maiores em
pacientes mais idosos (p = 0,031). Na regressão linear múltipla, somente “dose máxima de
MTX” e “história familiar” permaneceram com associac¸ão signiﬁcativa com SENS (r2 = 0,73,
p  < 0,001 para ambas as variáveis). No modelo que avaliou “CDAI”, apenas “dose máxima de
MTX” permaneceu com associac¸ão signiﬁcativa (r2 = 0,35, p = 0,016).
Conclusão: Na coorte Sarar, fatores clínicos e laboratoriais estiveram relacionados à ativi-
dade  de doenc¸a, capacidade funcional e dano radiológico, semelhantemente a estudos que
avaliaram pacientes com menor tempo de doenc¸a.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.
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heumatoid arthritis (RA) is a common disease in Brazil,
ffecting 0.2–1% of the Brazilian population.1 Brazilian guide-
ines for treating RA recommend early use of at least one
isease-modifying anti-rheumatic drugs (DMARDs), with or
ithout the use of corticosteroids, since the onset of the
isease.2 The main objective is to prevent or at least slow the
rogression of radiographic joint damage, which can lead to
eformities and functional disability, with reduced quality of
ife and work capacity. However, the treatment of RA is often
uboptimal in our environment3 and, therefore, many  patients
evelop secondary osteoarthritis, requiring surgical treatment
ith total arthroplasties, signiﬁcantly increasing health care
osts.4
The SARAH Network is a reference center for rehabilitation
n Brazil, with units in several Brazilian states, including the
ederal District. In this context, the institution focuses on the
reatment of patients with RA or juvenile idiopathic arthritis
JIA) at an advanced stage, with permanent sequelae of the
isease by means of orthopedic surgeries and rehabilitation.
The Sarar cohort consists of adult patients of all age groups,
atients with long-standing RA or JIA, with great functional
isability and extensive radiological damage, participating in
 rehabilitation program and having orthopedic treatment for
equelae of the disease in the hospital SARAH-Brasília. Its goal
s to evaluate these patients’ long-term progress after under-
oing primary or review total hip and/or knee replacement.Patients are usually referred from public or private rheuma-
tology clinics, for rehabilitation. The inclusion of patients in
the cohort began in October 2008 and ended in January 2013.
After the initial inclusion, patients were evaluated in some of
their follow-up visits with the Orthopedics team.
The clinical characteristics of patients with RA who  are
candidates for orthopedic surgery can inﬂuence the degree of
disability and instability at work,5 inﬂammatory activity and
radiological damage.6 Therefore, the objective of this study is
to evaluate the clinical, radiological and laboratory proﬁle of
RA patients followed by the Sarar cohort, and evaluate which
factors are associated with disease activity, functional capac-
ity and radiological damage.
Methods
Study  design
Cross-sectional analysis of data from the Sarar cohort with
data collection achieved from medical chart review.
Inclusion  and  exclusion  criteria
We  included all patients aged ≥18 years admitted at the Adult
Orthopedics and Neurosurgery Department to undergo total
hip (THA) or knee (TKA) arthroplasty at the hospital Sarah-
Brasilia, who had RA with diagnosis established according
to the criteria of the American College of Rheumatology.7 As
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explained above, patient inclusion occurred between October
2008 and January 2013.
RA patients have been excluded if: the indication of arthro-
plasty was due to avascular necrosis, other inﬂammatory
diseases justiﬁed the articular condition better than RA,
and patients who underwent previous arthroplasty during
the inclusion period. Speciﬁcally in this study, we excluded
patients with JIA.
Data  collection
The standardized assessment was performed by means of
the electronic medical record data review, supplemented by
patient interview when needed, one day before the date
of the proposed surgery. The following data were recorded:
duration of disease; time interval between the onset of
symptoms and the correct diagnosis; date of initiation
of treatment with DMARDs with description of medica-
tions on prior and current use, including the dose; time
of follow-up with a rheumatologist; preoperative orthope-
dic diagnosis; associated autoimmune conditions; history
of smoking; family history of RA; presence of rheumatoid
factor (RF) and anti-cyclic citrullinated peptide antibody 3
(anti-CCP3), both by ELISA, when available, with the most
recent date of examination in the medical record being
considered.
Inﬂammatory activity was assessed with the Clinical Dis-
ease Activity Index (CDAI),8 which takes the count of tender
and swollen joints, together with the overall health assess-
ment score by the patient and the physician, by visual analog
scale, into account for its calculation.
Preoperative functional capacity was assessed with the
Health Assessment Questionnaire-Disability Index (HAQ)
translated and validated for the Portuguese language, and self-
administered.9,10
The established joint damage was assessed with simple
digital radiographs of hands and feet using the Simpliﬁed Ero-
sion Narrowing Score (SENS),11 which counts the number of
joints in which there is the presence of joint space narrow-
ing and/or erosions. For this assessment, we used the Eﬁlm
Workstation software version 2.1.2, which allowed the use of
image magniﬁcation features. A rheumatologist examined all
radiographs (BMC).
The study was approved by the Research Ethics Committee
of the SARAH Network, registered at Plataforma Brasil with
the number 07477412.2.0000.0022.
Statistical  analysis
Descriptive analysis was performed. RF values and anti-
CCP3 were divided into four categories, with the former
according to the quartiles, and the latter to negative, weakly
positive, moderately positive and strongly positive, accord-
ing to the manufacturer’s references. Spearman correlation
tests were performed between continuous independent vari-
ables and the dependent variables (CDAI, HAQ and SENS).
Mann–Whitney U test was performed for comparison of
means including independent variables with two categories,
and the Kruskal–Wallis H test for comparison of means 0 1 5;5 5(5):420–426
including independent variables with more  than two cate-
gories being conducted.
Subgroup analysis was performed among patients under-
going THA and TKA.
Multiple linear regression model was developed, includ-
ing the independent variables with signiﬁcant association,
assuming a normal distribution of data.
To verify the intra-examiner variability of evaluation of
radiographs, we  calculated the intraclass correlation coefﬁ-
cient, model 3.112 and performed paired t-test including 10
patients who were randomly selected by a computer program
among the study sample.
The software used was the SOFA version 1.4.0 and SPSS
version 21.
Results
Thirty-two patients were included, with 28 female patients.
The mean age was 59 years old (40–84). Most patients lived
in the Federal District (24 individuals), but 5 patients from
the state of Minas Gerais, one from the state of Paraíba, one
from Tocantins and 1 from Sao Paulo were included. Patients
referred by the Brazilian National Health Service (SUS) totaled
44% of cases; within patients from places other than the Fed-
eral District, only one was followed in a public health center.
Seventeen patients were retired. Nineteen patients underwent
TKA and 17, THA.
Five patients were not regularly followed by a rheuma-
tologist. Forty-eight percent of patients had missed rheuma-
tologist follow-up for a period, since the ﬁrst contact with
the specialist. Among the patients who had intervals with-
out rheumatology monitoring, unaccompanied average time
was 45 months (0–432).
The average time between the onset of the disease and the
surgery was 240 months (47–506) and the mean time between
onset of symptoms and the diagnosis of RA was 27 months
(1–369). Thirteen patients were current or previous smokers
and 16 patients had family history of RA in ﬁrst-degree rela-
tives.
Eighty-seven percent of the patients had active disease
(39% mild activity, 23% moderate and 26% severe), with a
mean CDAI of 14.7 (0.5–56.4). The average duration of morn-
ing stiffness was 25 min  (0–240). The average HAQ was 1.8
(0.25–2.875).
Twenty-seven patients were taking DMARDs (Table 1),
although 3 of these patients had reported having used <80% of
doses. Considering the previous and current use, methotrex-
ate (MTX) was taken by 84% of the patients during follow-up,
but only 41% were on current treatment. The maximum dose
prescribed by rheumatologists in the course of the disease
was on average 15.1 mg  (2.5–20). Five patients have never been
treated with MTX, including one with 115 months of dis-
ease duration. Only two patients did not receive antimalarial
drugs during follow-up. Leﬂunomide was taken by 66% of the
patients, sulfasalazine by 31% and gold salts by 22%. Among
the biological drugs (received by 31% of the patients), the most
frequent were etanercept and adalimumab, with four cases
each.
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Table 1 – Current use of disease-modifying drugs (DMARDs).
DMARD n Dose
Mean SD min–max
Methotrexate (mg/week) 13 14.4 2.9 2.5–20
Leﬂunomide (mg/day) 15 20 0 20
Sulfasalazine (mg/day) 2 750 350 500–1000
Chloroquine (mg/day) 5 250 0 250
Hydroxychloroquine (mg/day) 3 333.3 115.5 200–400
Inﬂiximab (mg/dose) 1 200 0 200
Etanercept (mg/week) 2 50 0 50
Adalimumab (mg/dose) 3 40 0 40
Rituximab (mg/dose) 2 2000 0 2000
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model explained approximately 73% of the variability of SENS.Abatacept (mg/dose) 1 
Complications directly related to surgery occurred in
even cases, with three being dislocations of prosthesis, a
eriprosthetic fracture, a surgical site infection, a graft infec-
ion and a heterotopic ossiﬁcation.
Among the associated autoimmune conditions, the only
ne present was thyroid autoimmune disease (hypo- or hyper-
hyroidism) in 34% of the patients.
RF was positive in 51% of the patients, with a mean value of
71 U/ml (29–3140). The anti-CCP3 was positive in 62% of cases,
eing weakly positive in 3%, moderate in 9%, and strongly
ositive in 50%. The average SENS was 34.8 (1–75).
When the dependent variable “CDAI” was analyzed, a neg-
tive correlation was found with time of disease onset, and a
ositive one with the maximum dose of MTX. Moreover, a posi-
ive correlation was found between HAQ and age, and between
ENS and the maximum dose of MTX  (Table 2).
On comparison of means, when the dependent variables
CDAI” and “HAQ” were assessed, no signiﬁcant associations
Table 2 – Spearman Correlation Tests among continuous
independent variables, Health Assessment
Questionnaire (HAQ), Clinical Disease Activity Index
(CDAI) and Simpliﬁed Erosion Narrowing Score (SENS).
R CI p
CDAI
Age −0.04 −0.39; 0.32 0.816
Time onset −0.46 −0.70; −0.12 0.011
 time-diag 0.17 −0.20; 0.50 0.365
MTX Max Dose 0.55 0.22; 0.77 0.003
HAQ
Age 0.39 0.04; 0.65 0.031
Time onset 0.07 −0.3; 0.42 0.704
 time-diag 0.08 −0.29; 0.43 0.676
MTX Max Dose 0.01 −0.37; −0.39 0.957
SENS
Age −0.09 −0.45; 0.29 0.653
Time onset 0.32 −0.07; 0.62 0.101
 time-diag 0.16 −0.23; 0.51 0.431
MTX Max Dose −0.58 −0.80; −0.22 0.004
t onset-diag, time span between symptoms appearance and diag-
nosis; MTX, methotrexate.0 500
were found. In the analysis of the dependent variable “SENS”,
a positive association was found with the presence of RF and
Anti-CCP3, and a negative one with smoking and family his-
tory of RA. Patients were stratiﬁed into categories, according
to the titers of RF and Anti-CCP3, with the highest titers being
associated with higher SENS values (Table 3).
The multiple linear regression model included the clini-
cal and laboratory variables with signiﬁcant association with
SENS and CDAI. Regarding the dependent variable “SENS”,
two models were constructed, one including the RF and anti-
CCP3 as categorical variables (present or absent) and another
one as ordinal variables. In both of them, only the variables
“maximum dose of MTX” and “family history” remained with
signiﬁcant association (p < 0.001 in both variables). The ﬁnalIn the model that evaluated the independent variable “CDAI”,
Table 3 – Mann–Whitney and Kruskal–Wallis tests for
comparison among groups with presence or absence of
clinical and laboratory variables.
Variable CDAI HAQ SENS
p
Positive RF 0.563 0.611 0.005
RF titer (1–4) 0.532 0.181 0.037
Anti-CCP3 + 0.351 0.301 0.044
Anti-CCP3 titer (1 × 4) 0.575 0.458 0.025
Gender 0.86 0.616 0.87
Smoking 0.936 0.054 0.08
Family history of RA 0.58 0.406 0.009
MTX 0.724 0.204 0.674
LFN 0.833 0.611 0.51
SSZ 0.151 0.719 0.811
Antimalarial 0.127 0.778 0.964
Gold Salts 0.108 0.124 0.466
Biological drug 0.057 0.33 0.98
TKA 0.776 0.109 0.502
HAQ, Health Assessment Questionnaire; CDAI, Clinical Disease Activ-
ity Index;  SENS, Simpliﬁed Erosion Narrowing Score; RF, rheumatoid
factor. RF titers were divided according to the quartiles. Anti-
CCP3, anti-cyclic citrullinated peptide antibody 3. Anti-CCP3 titers
were divided in negative, weakly positive, moderately positive and
strongly positive. MTX, methotrexate; LFN, leﬂunomide; SSZ, sul-
fasalazine; TKA, total knee arthroplasty; RA, rheumatoid arthritis.
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only “maximum MTX  dose” remained signiﬁcantly associated
(r2 = 0.35, p = 0.016).
There were no signiﬁcant differences between patients
undergoing THA and TKA, for CDAI, HAQ and SENS.
The intraclass correlation coefﬁcient for the evaluation of
10 radiographs was 0.92 (95% CI 0.73–0.98) and the average
difference among peer evaluations was 3.4 (SD 7.183). There
was no signiﬁcant difference (p = 0.169).
Discussion
Our results identiﬁed possible improvements that could be
implemented in the management of patients with RA who
are referred for rehabilitation and surgery. The small num-
ber of patients who were in current use of MTX, the main
drug for RA treatment, is notable. This can be explained in
part because they are long-standing patients, who in many
cases were exposed to medication for a long time, which
can increase the chance of medication discontinuation due to
adverse events13,14 mainly in the liver.15 Furthermore, some
patients might not have had a good response to the medica-
tion. On the other hand, 49% of the patients had moderate
to severe inﬂammatory disease activity, what we consider an
inappropriate situation in the perioperative setting. This can-
not be justiﬁed only by the severity of the cases, since many
patients had suboptimal dose of DMARDs. Joints with dam-
age may have persistent inﬂammation. If drug therapy was
optimized, patients with active disease could express less
pain symptoms in the joint where the surgery was indicated,
and surgery could be postponed. Additionally, disease activity
makes patients more  disabled, which can reduce compliance
to rehabilitation activities.
The frequency of RF positivity and anti-CCP3 was lower
than that reported in the international literature, but similar to
that found in Brasilia cohort,16 composed of early RA patients
whose initial blood samples were collected before treatment.
In that study, RF titers increased after one year, which may
explain the mean titer of RF being much higher than in our
study. These data contrast with the description by Bos et al.,
on which a reduction of RF levels or even negativation of test
results was observed in some of the cases after initiation of
adalimumab treatment,17 and with the study by Vaz et al., in
which there was signiﬁcant reduction in anti-CCP titers during
treatment with inﬂiximab.18 These ﬁndings may be related to
speciﬁc characteristics of anti-TNF inhibitors.
Similarly to this study, other groups have found no corre-
lation between the positivity or titers of RF with functional
capacity and disease activity.19,20 The association between RF
positivity and radiographic progression is known, especially in
patients with early disease21,22 but how the joint damage accu-
mulates over decades is not known. In this study, there was
no independent correlation between RF and SENS, but patients
of an average of 20 years of disease onset with many  accumu-
lated joint damage were evaluated. Note that no correlation
was found between age and radiological damage, suggesting
that damage appearance can get stable over time.
There was a positive correlation between age and func-
tional ability, irrespective of the degree of radiological damage, 0 1 5;5 5(5):420–426
suggesting that other factors are inﬂuencing HAQ, for exam-
ple, the natural aging process.23
In our study, smoking was not independently associated
to greater radiographic progression. The results contrast with
those of a prospective study by Vesperini et al., who  recently
showed a lower risk of progression in patients with early RA,24
but are in agreement with the results of two other studies.25,26
Conversely, the study by Ruiz-Esquide et al. demonstrated
greater radiographic progression in smokers.27 Therefore, the
association between smoking and radiographic progression is
still controversial.
Regarding family history of RA, the results of this study con-
tradict those by Rojas-Villajaga et al., which demonstrated that
early RA patients with a family history developed radiographic
damage more  quickly, although the cumulative damage was
not evaluated,28 as was the case in our study, which evaluated
patients with long-standing disease. Factors such as ethnic
differences, disease duration, differences in treatment with
DMARDs, and radiographic evaluation methods can be the
origin of this disparity.
Patients with long-standing disease activity have a higher
cumulative radiological damage,29 which may explain the
use of larger previous doses of MTX in patients with higher
SENS and CDAI values, because they probably had, through-
out evolution, activity of the disease that is more  difﬁcult to
control.
The Sarar cohort, in a way, makes an interesting counter-
point to the Brasília cohort, once it comes to patients with
advanced disease, from the same region of Brazil. To our
knowledge, this is the ﬁrst study in Brazil that assessed dis-
ease activity, functional capacity and radiological damage in
patients with RA of such long-standing disease, which is inter-
esting in a time when all eyes are focused on patients with
early RA. Currently, a change in the evaluation and manage-
ment of patients with RA undergoing rehabilitation treatment
at SARAH-Brasilia hospital is being planned, motivated by the
results of this study, so that such patients are grouped for
rehabilitation at a specialized clinic.
This study has limitations. It is a cross-sectional study, the
ﬁndings of which require conﬁrmation in prospective studies;
temporal data and maximum doses of DMARDs were reported
by the patients who recovered it from memory,  which can
lead to inaccuracies (e.g., the assessment of family history),
considering the long term of the disease; RF detection had
great temporal variation preceding hospitalization, so in some
cases they may not have represented the current immune
status of patients; due to technical reasons related to the
bidimensionality of the radiographs, it was not possible to
assess the SENS of a patient with severe deformities, which
excluded from the analysis a case with very severe radiological
changes.
In summary, patients of the Sarar cohort treated at the
hospital SARAH-Brasilia, received a late diagnosis of RA in
their health centers of origin. About half of the patients had
moderate to severe inﬂammatory activity, with non-optimized
treatment according to the consensus of the Brazilian Soci-
2ety of Rheumatology and the recommendations of the RA
Treat To Target.30 Patients with family history of RA had less
radiological damage, while patients using higher maximum
dose of MTX had major damage. Older patients had greater
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unctional disability. The maximum dose of MTX  during evo-
ution was associated with higher disease activity.
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